The Importance of Cost-Effectiveness in New Drug Approval: Stroke Burden and Tenecteplase Efficacy.
作者信息
Kwon Hyuk Sung, Kim Byung-Jo
机构信息
Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Department of Neurology, Korea University Anam Hospital, Korea University Medicine, Seoul, Korea.
出版信息
J Clin Neurol. 2025 Sep;21(5):363-364. doi: 10.3988/jcn.2025.0372.
Abstract
摘要
相似文献
1
The Importance of Cost-Effectiveness in New Drug Approval: Stroke Burden and Tenecteplase Efficacy.成本效益在新药审批中的重要性：中风负担与替奈普酶疗效
J Clin Neurol. 2025 Sep;21(5):363-364. doi: 10.3988/jcn.2025.0372.
2
Tenecteplase Versus Alteplase for Acute Stroke: Mortality and Bleeding Complications.替奈普酶与阿替普酶治疗急性脑卒中：死亡率和出血并发症。
Ann Emerg Med. 2023 Dec;82(6):720-728. doi: 10.1016/j.annemergmed.2023.03.022. Epub 2023 May 12.
3
Efficacy and safety of tenecteplase in comparison to alteplase in acute ischemic stroke: A systematic review and meta-analysis of randomized controlled trials.替奈普酶与阿替普酶治疗急性缺血性脑卒中的疗效和安全性：系统评价和随机对照试验的荟萃分析。
Clin Neurol Neurosurg. 2023 Oct;233:107961. doi: 10.1016/j.clineuro.2023.107961. Epub 2023 Sep 9.
4
Lack of Interactions Between Alteplase/Tenecteplase and the Adenosine A1R/A3R Agonist AST-004.阿替普酶/替奈普酶与腺苷 A1R/A3R 激动剂 AST-004 之间缺乏相互作用。
Stroke. 2024 Jul;55(7):1923-1926. doi: 10.1161/STROKEAHA.124.046688. Epub 2024 May 31.
5
Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke.替奈普酶和阿替普酶治疗急性缺血性卒中的短期安全性和有效性
JAMA Netw Open. 2025 Mar 3;8(3):e250548. doi: 10.1001/jamanetworkopen.2025.0548.
6
Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy: The ANGEL-TNK Randomized Clinical Trial.血管内治疗成功后动脉内注射替奈普酶治疗急性卒中：ANGEL-TNK随机临床试验
JAMA. 2025 Jul 5. doi: 10.1001/jama.2025.10800.
7
A similar effect of fibrinogen on efficacy and safety of tenecteplase alteplase in acute ischemic cerebrovascular events (TRACE II) trial.纤维蛋白原对替奈普酶与阿替普酶治疗急性缺血性脑血管事件疗效和安全性影响的相似性（TRACE II）试验
J Transl Int Med. 2025 Apr 18;13(3):295-303. doi: 10.1515/jtim-2025-0010. eCollection 2025 Jun.
8
Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial.血管内再灌注治疗大血管闭塞急性缺血性卒中后动脉内注射替奈普酶：POST-TNK随机临床试验
JAMA. 2025 Feb 18;333(7):579-588. doi: 10.1001/jama.2024.23466.
9
Efficacy and Safety of Tenecteplase in Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.替奈普酶治疗急性缺血性卒中的疗效与安全性：一项随机对照试验的荟萃分析
Brain Behav. 2025 Sep;15(9):e70791. doi: 10.1002/brb3.70791.
10
Comparative efficacy and safety of tenecteplase and alteplase in acute ischemic stroke: A pairwise and network meta-analysis of randomized controlled trials.替奈普酶与阿替普酶治疗急性缺血性卒中的疗效和安全性比较：随机对照试验的成对和网状荟萃分析
J Neurol Sci. 2023 Feb 15;445:120537. doi: 10.1016/j.jns.2022.120537. Epub 2022 Dec 29.
本文引用的文献
1
Tenecteplase in Acute Ischemic Stroke: A Scientific Statement From the Korean Stroke Society.替奈普酶治疗急性缺血性卒中：韩国卒中协会科学声明
J Clin Neurol. 2025 Sep;21(5):384-396. doi: 10.3988/jcn.2025.0210.
2
Challenges in Translating Recent RCTs on Endovascular Therapy for Large Core Infarctions Into Real-World Practice.将近期关于大核心梗死血管内治疗的随机对照试验转化为实际临床应用中的挑战
J Clin Neurol. 2025 May;21(3):230-231. doi: 10.3988/jcn.2025.0108.
3
World Stroke Organization: Global Stroke Fact Sheet 2025.世界卒中组织：《2025年全球卒中情况说明书》
Int J Stroke. 2025 Feb;20(2):132-144. doi: 10.1177/17474930241308142. Epub 2025 Jan 3.
4
Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球、区域和国家的卒中负担及其风险因素，1990-2021 年：2021 年全球疾病负担研究的系统分析。
Lancet Neurol. 2024 Oct;23(10):973-1003. doi: 10.1016/S1474-4422(24)00369-7.
5
Incidence and case fatality of stroke in Korea, 2011-2020.韩国 2011-2020 年脑卒中发病率和病死率。
Epidemiol Health. 2024;46:e2024003. doi: 10.4178/epih.e2024003. Epub 2023 Dec 26.
6
Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission.减少全球卒中负担的务实解决方案：世界卒中组织-柳叶刀神经病学委员会。
Lancet Neurol. 2023 Dec;22(12):1160-1206. doi: 10.1016/S1474-4422(23)00277-6. Epub 2023 Oct 9.
7
Real-World Impact of Modern Reperfusion Therapy for Acute Ischemic Stroke : A Nationwide Population-Based Data Study in Korea.现代再灌注治疗对急性缺血性卒中的真实世界影响：韩国一项基于全国人群的数据研究。
J Korean Neurosurg Soc. 2024 Mar;67(2):186-193. doi: 10.3340/jkns.2023.0133. Epub 2023 Oct 6.
8
Interactive Direct Interhospital Transfer Network System for Acute Stroke in South Korea.韩国急性卒中交互式直接医院间转运网络系统
J Clin Neurol. 2023 Mar;19(2):125-130. doi: 10.3988/jcn.2022.0158. Epub 2023 Jan 2.
9
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.替奈普酶与阿替普酶治疗挪威急性缺血性卒中（NOR-TEST 2，A部分）：一项3期随机开放标签盲终点非劣效性试验
Lancet Neurol. 2022 Jun;21(6):511-519. doi: 10.1016/S1474-4422(22)00124-7. Epub 2022 May 4.
10
Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.替奈普酶在急性心肌梗死溶栓治疗中的药代动力学和药效学
Clin Pharmacokinet. 2002;41(15):1229-45. doi: 10.2165/00003088-200241150-00001.
Zotero 插件